2,4-二羟基-5-羧酸-嘧啶 | 811450-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,4-二羟基-5-羧酸-嘧啶
• 英文名称: 2,4-dihydroxy-5-carboxylic acid-pyrimidine
• 英文别名: 4-Chloro-2-oxo-1,2-dihydropyrimidine-5-carboxylic acid；6-chloro-2-oxo-1H-pyrimidine-5-carboxylic acid
• CAS: 811450-35-8
• 化学式: C₅H₃ClN₂O₃
• 分子量: 174.543
• InChiKey: IWDHKISLFQKOLV-UHFFFAOYSA-N

物化性质

• 密度：
  1.83±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二羟基-5-羧酸-嘧啶 在 五氯化磷 、 三氯氧磷 作用下， 反应 5.0h， 以84%的产率得到2,4-二氯-5-嘧啶甲酰氯
  参考文献：
  名称：

  Macrocyclic pyrimidines, their production and use as pharmaceutical agents

  摘要：

  通用公式I的大环嘧啶衍生物 其中R1至R5，X，Y，A，B，m和n的含义如描述中所含，作为细胞周期依赖性激酶抑制剂，它们的生产过程以及它们作为治疗各种疾病的药物的用途被描述。

  公开号：

  US20040209895A1

文献信息

• INHIBITORS OF SYK AND JAK PROTEIN KINASES
  申请人：Jia Zhaozhong

  公开号：US20120130073A1

  公开（公告）日：2012-05-24

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V化合物及其互变异构体或药学上可接受的盐、酯和前药，这些化合物是syk激酶的抑制剂。本发明还涉及用于制备这些化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种疾病的方法，例如不良血栓形成和非霍奇金淋巴瘤。
• INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
  申请人：H. Lee Moffitt Cancer Center And Research Institute, Inc.

  公开号：US20180155297A1

  公开（公告）日：2018-06-07

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
• US8318755B2
  申请人：——

  公开号：US8318755B2

  公开（公告）日：2012-11-27
• Macrocyclic pyrimidines, their production and use as pharmaceutical agents
  申请人：Schering AG

  公开号：US20040209895A1

  公开（公告）日：2004-10-21

  Macrocyclic pyrimidine derivatives of general formula I 1 in which R 1 to R 5 , X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.

  通用公式I的大环嘧啶衍生物 其中R1至R5，X，Y，A，B，m和n的含义如描述中所含，作为细胞周期依赖性激酶抑制剂，它们的生产过程以及它们作为治疗各种疾病的药物的用途被描述。